Skip to main content
Erschienen in: Pediatric Cardiology 7/2022

08.04.2022 | Original Article

Autologous Cardiac Stem Cell Injection in Patients with Hypoplastic Left Heart Syndrome (CHILD Study)

verfasst von: Sunjay Kaushal, Joshua M. Hare, Aakash M. Shah, Nicholas P. Pietris, Judith L. Bettencourt, Linda B. Piller, Aisha Khan, Abigail Snyder, Riley M. Boyd, Mohamed Abdullah, Rachana Mishra, Sudhish Sharma, Timothy C. Slesnick, Ming-Sing Si, Paul J. Chai, Barry R. Davis, Dejian Lai, Michael E. Davis, William T. Mahle

Erschienen in: Pediatric Cardiology | Ausgabe 7/2022

Einloggen, um Zugang zu erhalten

Abstract

Mortality in infants with hypoplastic left heart syndrome (HLHS) is strongly correlated with right ventricle (RV) dysfunction. Cell therapy has demonstrated potential improvements of RV dysfunction in animal models related to HLHS, and neonatal human derived c-kit+ cardiac-derived progenitor cells (CPCs) show superior efficacy when compared to adult human cardiac-derived CPCs (aCPCs). Neonatal CPCs (nCPCs) have yet to be investigated in humans. The CHILD trial (Autologous Cardiac Stem Cell Injection in Patients with Hypoplastic Left Heart Syndrome) is a Phase I/II trial aimed at investigating intramyocardial administration of autologous nCPCs in HLHS infants by assessing the feasibility, safety, and potential efficacy of CPC therapy. Using an open-label, multicenter design, CHILD investigates nCPC safety and feasibility in the first enrollment group (Group A/Phase I). In the second enrollment group, CHILD uses a randomized, double-blinded, multicenter design (Group B/Phase II), to assess nCPC efficacy based on RV functional and structural characteristics. The study plans to enroll 32 patients across 4 institutions: Group A will enroll 10 patients, and Group B will enroll 22 patients. CHILD will provide important insights into the therapeutic potential of nCPCs in patients with HLHS.
Clinical Trial Registration https://​clinicaltrials.​gov/​ct2/​home NCT03406884, First posted January 23, 2018.
Literatur
8.
Zurück zum Zitat Ohye RG, Sleeper LA, Mahony L, Newburger JW, Pearson GD, Lu M, Goldberg CS, Tabbutt S, Frommelt PC, Ghanayem NS, Laussen PC, Rhodes JF, Lewis AB, Mital S, Ravishankar C, Williams IA, Dunbar-Masterson C, Atz AM, Colan S, Minich LL, Pizarro C, Kanter KR, Jaggers J, Jacobs JP, Krawczeski CD, Pike N, McCrindle BW, Virzi L, Gaynor JW, Investigators PHN (2010) Comparison of shunt types in the Norwood procedure for single-ventricle lesions. N Engl J Med 362:1980–1992. https://doi.org/10.1056/NEJMoa0912461CrossRefPubMedPubMedCentral Ohye RG, Sleeper LA, Mahony L, Newburger JW, Pearson GD, Lu M, Goldberg CS, Tabbutt S, Frommelt PC, Ghanayem NS, Laussen PC, Rhodes JF, Lewis AB, Mital S, Ravishankar C, Williams IA, Dunbar-Masterson C, Atz AM, Colan S, Minich LL, Pizarro C, Kanter KR, Jaggers J, Jacobs JP, Krawczeski CD, Pike N, McCrindle BW, Virzi L, Gaynor JW, Investigators PHN (2010) Comparison of shunt types in the Norwood procedure for single-ventricle lesions. N Engl J Med 362:1980–1992. https://​doi.​org/​10.​1056/​NEJMoa0912461CrossRefPubMedPubMedCentral
9.
Zurück zum Zitat Feinstein JA, Benson DW, Dubin AM, Cohen MS, Maxey DM, Mahle WT, Pahl E, Villafaňe J, Bhatt AB, Peng LF, Johnson BA, Marsden AL, Daniels CJ, Rudd NA, Caldarone CA, Mussatto KA, Morales DL, Ivy DD, Gaynor JW, Tweddell JS, Deal BJ, Furck AK, Rosenthal GL, Ohye RG, Ghanayem NS, Cheatham JP, Tworetzky W, Martin GR (2012) Hypoplastic left heart syndrome: current considerations and expectations. J Am Coll Cardiol 59(1 Suppl):S1-42. https://doi.org/10.1016/j.jacc.2011.09.022CrossRefPubMedPubMedCentral Feinstein JA, Benson DW, Dubin AM, Cohen MS, Maxey DM, Mahle WT, Pahl E, Villafaňe J, Bhatt AB, Peng LF, Johnson BA, Marsden AL, Daniels CJ, Rudd NA, Caldarone CA, Mussatto KA, Morales DL, Ivy DD, Gaynor JW, Tweddell JS, Deal BJ, Furck AK, Rosenthal GL, Ohye RG, Ghanayem NS, Cheatham JP, Tworetzky W, Martin GR (2012) Hypoplastic left heart syndrome: current considerations and expectations. J Am Coll Cardiol 59(1 Suppl):S1-42. https://​doi.​org/​10.​1016/​j.​jacc.​2011.​09.​022CrossRefPubMedPubMedCentral
13.
15.
Zurück zum Zitat Hatzistergos KE, Takeuchi LM, Saur D, Seidler B, Dymecki SM, Mai JJ, White IA, Balkan W, Kanashiro-Takeuchi RM, Schally AV, Hare JM (2015) cKit+ cardiac progenitors of neural crest origin. Proc Natl Acad Sci USA 112:13051–13056CrossRef Hatzistergos KE, Takeuchi LM, Saur D, Seidler B, Dymecki SM, Mai JJ, White IA, Balkan W, Kanashiro-Takeuchi RM, Schally AV, Hare JM (2015) cKit+ cardiac progenitors of neural crest origin. Proc Natl Acad Sci USA 112:13051–13056CrossRef
16.
Zurück zum Zitat Hatzistergos KE, Durante MA, Valasaki K, Wanschel AC, Harbour JW, Hare JM (2020) A novel cardiomyogenic role for Isl1+ neural crest cells in the inflow tract. Sci Adv 6:eaba9950CrossRef Hatzistergos KE, Durante MA, Valasaki K, Wanschel AC, Harbour JW, Hare JM (2020) A novel cardiomyogenic role for Isl1+ neural crest cells in the inflow tract. Sci Adv 6:eaba9950CrossRef
17.
Zurück zum Zitat van Berlo JH, Kanisicak O, Maillet M, Vagnozzi RJ, Karch J, Lin SC, Middleton RC, Marbán E, Molkentin JD (2014) c-kit+ cells minimally contribute cardiomyocytes to the heart. Nature 509:337–341CrossRef van Berlo JH, Kanisicak O, Maillet M, Vagnozzi RJ, Karch J, Lin SC, Middleton RC, Marbán E, Molkentin JD (2014) c-kit+ cells minimally contribute cardiomyocytes to the heart. Nature 509:337–341CrossRef
23.
Zurück zum Zitat Bolli R, Hare JM, March KL, Pepine CJ, Willerson JT, Perin EC, Yang PC, Henry TD, Traverse JH, Mitrani RD, Khan A, Hernandez-Schulman I, Taylor DA, DiFede DL, Lima JA, Chuch A, Loughran J, Vojvodic RW, Sayre SL, Bettencourt J, Cohen M, Moyé L, Ebert RF, Simari RD, Cardiovascular Cell Therapy Research Network (CCTRN) (2018) Rationale and design of the CONCERT-HF Trial (Combination of Mesenchymal and c-kit+ cardiac stem cells as regenerative therapy for heart failure). Circ Res 122:1703–1715. https://doi.org/10.1161/CIRCRESAHA.118.312978CrossRefPubMedPubMedCentral Bolli R, Hare JM, March KL, Pepine CJ, Willerson JT, Perin EC, Yang PC, Henry TD, Traverse JH, Mitrani RD, Khan A, Hernandez-Schulman I, Taylor DA, DiFede DL, Lima JA, Chuch A, Loughran J, Vojvodic RW, Sayre SL, Bettencourt J, Cohen M, Moyé L, Ebert RF, Simari RD, Cardiovascular Cell Therapy Research Network (CCTRN) (2018) Rationale and design of the CONCERT-HF Trial (Combination of Mesenchymal and c-kit+ cardiac stem cells as regenerative therapy for heart failure). Circ Res 122:1703–1715. https://​doi.​org/​10.​1161/​CIRCRESAHA.​118.​312978CrossRefPubMedPubMedCentral
24.
Zurück zum Zitat Kaushal S, Wehman B, Pietris N, Naughton C, Bentzen SM, Bigham G, Mishra R, Sharma S, Vricella L, Everett AD, Deatrick KB, Huang S, Mehta H, Ravekes WA, Hibino N, Difede DL, Khan A, Hare JM (2017) Study design and rationale for ELPIS: a phase I/IIb randomized pilot study of allogeneic human mesenchymal stem cell injection in patients with hypoplastic left heart syndrome. Am Heart J 192:48–56. https://doi.org/10.1016/j.ahj.2017.06.009CrossRefPubMed Kaushal S, Wehman B, Pietris N, Naughton C, Bentzen SM, Bigham G, Mishra R, Sharma S, Vricella L, Everett AD, Deatrick KB, Huang S, Mehta H, Ravekes WA, Hibino N, Difede DL, Khan A, Hare JM (2017) Study design and rationale for ELPIS: a phase I/IIb randomized pilot study of allogeneic human mesenchymal stem cell injection in patients with hypoplastic left heart syndrome. Am Heart J 192:48–56. https://​doi.​org/​10.​1016/​j.​ahj.​2017.​06.​009CrossRefPubMed
25.
Zurück zum Zitat Ishigami S, Ohtsuki S, Eitoku T, Ousaka D, Kondo M, Kurita Y, Hirai K, Fukushima Y, Baba K, Goto T, Horio N, Kobayashi J, Kuroko Y, Kotani Y, Arai S, Iwasaki T, Sato S, Kasahara S, Sano S, Oh H (2017) Intracoronary cardiac progenitor cells in single ventricle physiology: the PERSEUS (Cardiac progenitor cell infusion to treat univentricular heart disease) randomized phase 2 trial. Circ Res 120:1162–1173. https://doi.org/10.1161/CIRCRESAHA.116.310253CrossRefPubMed Ishigami S, Ohtsuki S, Eitoku T, Ousaka D, Kondo M, Kurita Y, Hirai K, Fukushima Y, Baba K, Goto T, Horio N, Kobayashi J, Kuroko Y, Kotani Y, Arai S, Iwasaki T, Sato S, Kasahara S, Sano S, Oh H (2017) Intracoronary cardiac progenitor cells in single ventricle physiology: the PERSEUS (Cardiac progenitor cell infusion to treat univentricular heart disease) randomized phase 2 trial. Circ Res 120:1162–1173. https://​doi.​org/​10.​1161/​CIRCRESAHA.​116.​310253CrossRefPubMed
26.
Zurück zum Zitat Ishigami S, Ohtsuki S, Tarui S, Ousaka D, Eitoku T, Kondo M, Okuyama M, Kobayashi J, Baba K, Arai S, Kawabata T, Yoshizumi K, Tateishi A, Kuroko Y, Iwasaki T, Sato S, Kasahara S, Sano S, Oh H (2015) Intracoronary autologous cardiac progenitor cell transfer in patients with hypoplastic left heart syndrome: the TICAP prospective phase 1 controlled trial. Circ Res 116:653–664. https://doi.org/10.1161/CIRCRESAHA.116.304671CrossRefPubMed Ishigami S, Ohtsuki S, Tarui S, Ousaka D, Eitoku T, Kondo M, Okuyama M, Kobayashi J, Baba K, Arai S, Kawabata T, Yoshizumi K, Tateishi A, Kuroko Y, Iwasaki T, Sato S, Kasahara S, Sano S, Oh H (2015) Intracoronary autologous cardiac progenitor cell transfer in patients with hypoplastic left heart syndrome: the TICAP prospective phase 1 controlled trial. Circ Res 116:653–664. https://​doi.​org/​10.​1161/​CIRCRESAHA.​116.​304671CrossRefPubMed
29.
Zurück zum Zitat Burkhart HM, Qureshi MY, Rossano JW, Cantero Peral S, O’Leary PW, Hathcock M, Kremers W, Nelson TJ, Wanek HLHS Consortium Clinical Pipeline (2019) Autologous stem cell therapy for hypoplastic left heart syndrome: safety and feasibility of intraoperative intramyocardial injections. J Thorac Cardiovasc Surg 158:1614–1623. https://doi.org/10.1016/j.jtcvs.2019.06.001CrossRefPubMed Burkhart HM, Qureshi MY, Rossano JW, Cantero Peral S, O’Leary PW, Hathcock M, Kremers W, Nelson TJ, Wanek HLHS Consortium Clinical Pipeline (2019) Autologous stem cell therapy for hypoplastic left heart syndrome: safety and feasibility of intraoperative intramyocardial injections. J Thorac Cardiovasc Surg 158:1614–1623. https://​doi.​org/​10.​1016/​j.​jtcvs.​2019.​06.​001CrossRefPubMed
32.
Zurück zum Zitat Bolli R, Mitrani RD, Hare JM, Pepine CJ, Perin EC, Willerson JT, Traverse JH, Henry TD, Yang PC, Murphy MP, March KL, Schulman IH, Ikram S, Lee DP, O’Brien C, Lima JA, Ostovaneh MR, Ambale-Venkatesh B, Lewis G, Khan A, Bacallao K, Valasaki K, Longsomboon B, Gee AP, Richman S, Taylor DA, Lai D, Sayre SL, Bettencourt J, Vojvodic RW, Cohen ML, Simpson L, Aguilar D, Loghin C, Moyé L, Ebert RF, Davis BR, Simari RD, Cardiovascular Cell Therapy Research Network (CCTRN) (2021) A phase II study of autologous mesenchymal stromal cells and c-kit positive cardiac cells, alone or in combination, in patients with ischaemic heart failure: the CCTRN CONCERT-HF trial. Eur J Heart Fail 23(4):661–674. https://doi.org/10.1002/ejhf.2178CrossRefPubMed Bolli R, Mitrani RD, Hare JM, Pepine CJ, Perin EC, Willerson JT, Traverse JH, Henry TD, Yang PC, Murphy MP, March KL, Schulman IH, Ikram S, Lee DP, O’Brien C, Lima JA, Ostovaneh MR, Ambale-Venkatesh B, Lewis G, Khan A, Bacallao K, Valasaki K, Longsomboon B, Gee AP, Richman S, Taylor DA, Lai D, Sayre SL, Bettencourt J, Vojvodic RW, Cohen ML, Simpson L, Aguilar D, Loghin C, Moyé L, Ebert RF, Davis BR, Simari RD, Cardiovascular Cell Therapy Research Network (CCTRN) (2021) A phase II study of autologous mesenchymal stromal cells and c-kit positive cardiac cells, alone or in combination, in patients with ischaemic heart failure: the CCTRN CONCERT-HF trial. Eur J Heart Fail 23(4):661–674. https://​doi.​org/​10.​1002/​ejhf.​2178CrossRefPubMed
33.
Zurück zum Zitat Hare JM, Fishman JE, Gerstenblith G, DiFede Velazquez DL, Zambrano JP, Suncion VY, Tracy M, Ghersin E, Johnston PV, Brinker JA, Breton E, Davis-Sproul J, Schulman IH, Byrnes J, Mendizabal AM, Lowery MH, Rouy D, Altman P, Wong Po Foo C, Ruiz P, Amador A, Da Silva J, McNiece IK, Heldman AW, George R, Lardo A (2012) Comparison of allogeneic vs autologous bone marrow-derived mesenchymal stem cells delivered by transendocardial injection in patients with ischemic cardiomyopathy: the POSEIDON randomized trial. JAMA 308:2369–2379. https://doi.org/10.1001/jama.2012.25321CrossRefPubMedPubMedCentral Hare JM, Fishman JE, Gerstenblith G, DiFede Velazquez DL, Zambrano JP, Suncion VY, Tracy M, Ghersin E, Johnston PV, Brinker JA, Breton E, Davis-Sproul J, Schulman IH, Byrnes J, Mendizabal AM, Lowery MH, Rouy D, Altman P, Wong Po Foo C, Ruiz P, Amador A, Da Silva J, McNiece IK, Heldman AW, George R, Lardo A (2012) Comparison of allogeneic vs autologous bone marrow-derived mesenchymal stem cells delivered by transendocardial injection in patients with ischemic cardiomyopathy: the POSEIDON randomized trial. JAMA 308:2369–2379. https://​doi.​org/​10.​1001/​jama.​2012.​25321CrossRefPubMedPubMedCentral
Metadaten
Titel
Autologous Cardiac Stem Cell Injection in Patients with Hypoplastic Left Heart Syndrome (CHILD Study)
verfasst von
Sunjay Kaushal
Joshua M. Hare
Aakash M. Shah
Nicholas P. Pietris
Judith L. Bettencourt
Linda B. Piller
Aisha Khan
Abigail Snyder
Riley M. Boyd
Mohamed Abdullah
Rachana Mishra
Sudhish Sharma
Timothy C. Slesnick
Ming-Sing Si
Paul J. Chai
Barry R. Davis
Dejian Lai
Michael E. Davis
William T. Mahle
Publikationsdatum
08.04.2022
Verlag
Springer US
Erschienen in
Pediatric Cardiology / Ausgabe 7/2022
Print ISSN: 0172-0643
Elektronische ISSN: 1432-1971
DOI
https://doi.org/10.1007/s00246-022-02872-6

Weitere Artikel der Ausgabe 7/2022

Pediatric Cardiology 7/2022 Zur Ausgabe

Screening-Mammografie offenbart erhöhtes Herz-Kreislauf-Risiko

26.04.2024 Mammografie Nachrichten

Routinemäßige Mammografien helfen, Brustkrebs frühzeitig zu erkennen. Anhand der Röntgenuntersuchung lassen sich aber auch kardiovaskuläre Risikopatientinnen identifizieren. Als zuverlässiger Anhaltspunkt gilt die Verkalkung der Brustarterien.

Niedriger diastolischer Blutdruck erhöht Risiko für schwere kardiovaskuläre Komplikationen

25.04.2024 Hypotonie Nachrichten

Wenn unter einer medikamentösen Hochdrucktherapie der diastolische Blutdruck in den Keller geht, steigt das Risiko für schwere kardiovaskuläre Ereignisse: Darauf deutet eine Sekundäranalyse der SPRINT-Studie hin.

Therapiestart mit Blutdrucksenkern erhöht Frakturrisiko

25.04.2024 Hypertonie Nachrichten

Beginnen ältere Männer im Pflegeheim eine Antihypertensiva-Therapie, dann ist die Frakturrate in den folgenden 30 Tagen mehr als verdoppelt. Besonders häufig stürzen Demenzkranke und Männer, die erstmals Blutdrucksenker nehmen. Dafür spricht eine Analyse unter US-Veteranen.

Adipositas-Medikament auch gegen Schlafapnoe wirksam

24.04.2024 Adipositas Nachrichten

Der als Antidiabetikum sowie zum Gewichtsmanagement zugelassene Wirkstoff Tirzepatid hat in Studien bei adipösen Patienten auch schlafbezogene Atmungsstörungen deutlich reduziert, informiert der Hersteller in einer Vorab-Meldung zum Studienausgang.

Update Kardiologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.